|Age:||18 and older|
|Keywords:||uterine, ovarian, cervical, kinase, cancer, radiotherapy, phase 1, phase I, phase one|
|Type:||Drug study, Phase 1|
All study participants will receive the study drug AZD1775 given with standard radiotherapy and cisplatin. AZD1775 is a capsule that you will take by mouth once a day. Some days you will take the capsules in the hospital, but other days you will take AZD1775 at home. The dose of the AZD1775 you receive will depend on when you enroll in the study. The study doctor will tell you to which of the following groups you have been assigned:
Group 1: dose escalation
Different doses of the study drug AZD1775 will be given to several study participants. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until side effects occur that require the dose to be lowered.
Group 2: verifying the dose (expansion group)
The dose of AZD1775 identified in group 1 will be tested further in the next 15 participants. The dose of the study drug might be decreased or kept the same depending on the side effects.
Study schedules for groups 1 and 2:
The AZD1775 capsules will be taken on days 1, 3, 5 of each week, or on days 1-5 of each week. The study doctor will tell you which schedule you are on.
All participants will receive regular radiotherapy on days 1-5 for each week for 5 weeks, and regular Cisplatin chemotherapy on day 1 or day 3 of each week for 5 weeks
The Patient Study Drug Diary will explain how to take and record taking the study drug capsules and will also describe your schedule. The dose of the AZD1775 you receive can be lowered or delayed if there are excessive side effects.
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.